Friday, May 3, 2013

Stock Downgrades: MasterCard No Longer Quite So 'Priceless ...

The Fed had the best of intentions when it recently?pumped up its interest rate announcements to 2:00 p.m. Eastern. After all, the middle of Hump Day is when energy starts to sag, and who better than Ben Bernanke & Co to provide a sugar rush from which the economy appears utterly incapable of weaning itself off?
?
Unfortunately, it did not have the desired effect yesterday, with?Dow Industrials?(^DJI) enduring their single worst FOMC session-swoon since September 21, 2011. Good thing that other Ben, ice cream purveyor Mr. Cohen, provided an antidote hypoglycemia when he?sold his company to corporate giant?Unilever?(UN) for a cool $325 million cash. Yesterday that stock hit the highest level in its history, inspiring all hippies who care not a jot about making money, and on May Day of all days.
?
For those who prefer this weekend?s ?Woodstock for Capitalists? to the Birkenstock-wearing real deal,?Berkshire Hathaway (NYSE:BRK.A) scored an exceedingly rare analyst initiation. In 1969, not everyone was traipsing through the mud in upstate New York, of course, though it may have seemed that way at the time. On the other coast a bunch of geeks in Silicon Valley started?Advanced Micro Devices (AMD) that same year. And based on yesterday?s 14.18%?S&P 500-best (^GSPC) jump in its shares, the nerds ultimately inherit the Earth.
?
We?re now more than two-thirds of way through earnings season, but key results continue to roll in. Among today?s standouts are American International Group?(AIG),?British Sky Broadcasting?(PINK:BSYBY), General Motors?(GM),?Gilead Sciences (GILD), Kellogg (K), Kraft Foods?(KRFT), LinkedIn?(LNKD),?Monster Worldwide?(MWW),?Royal Dutch Shell?(RDS-A), and Sanofi-Aventis (SNY).
?
Active Network?(ACTV): Troubled by an exodus of upper management, RBC Capital cuts the application software company to Sector Perform from Outperform.
?
Advanced Micro Devices?(AMD): Shares, after a great run yesterday, are now Neutral from Outperform at Macquarie.
?
Boston Beer?(SAM): Cr?dit Agricole cuts the recently surging stock to Underperform from Outperform amid valuation issues.
?
California Water Service?(CWT): Shares are downgraded to Hold from Buy at Brean Capital.
?
Columbia Sportswear?(COLM): COLM is cut to Hold at McAdams Wright Ragen.
?
Comstock Resources?(CRK): Shares are downgraded to Hold from Buy at Stifel due to issues including limited oil drilling inventory.
?
CONSOL Energy?(CNX): Morgan Stanley cuts the coal company to Overweight from Equal-Weight.
?
DXP Enterprises?(DXPE): BB&T Capital Markets moves the industrial equipment outfit to Hold from Buy.
?
Exelon?(EXC): The nuclear power play is now Hold from Buy with Wunderlich.
?
Franklin Resources?(BEN): BEN is now Neutral from Buy at Sterne Agee.
?
Hyatt Hotels?(H): The stock is downgraded to Neutral from Outperform at Credit Suisse.
?
Jack Henry & Associates?(JKHY): The business software stock downgraded to Market Perform from Outperform at Wells Fargo.
?
MasterCard?(NYSE:MA): Raymond James reduces its recommendation on the credit card company, famous for its??Priceless? advertising campaign, to Market Perform from Outperform. The US economy in the first quarter ?was definitely very choppy,? its Chief Financial Officer said.
?
Newport Corporation?(NEWP): Shares are downgraded to Hold from Buy at Needham.
?
Micron Technology?(MU): Cr?dit Agricole cuts the semiconductor stock to Underperform from Outperform.
?
SolarCity?(SCTY): Shares are now Neutral from Buy at Goldman Sachs.
?
Vivendi?(PINK:VIVEF): The giant French media firm gets downgraded to Equal Weight from Overweight by Barclays.
?
Williams Partners?(WPZ): Bank of America-Merrill Lynch lowers the limited partnership to Neutral from Buy.

(See also: New Stock Coverage: T-Mobile Gets Lukewarm Reception and Stock Upgrades: Comedy Central Owner Viacom Laughing All the Way to the Bank.)

No positions in stocks mentioned.

The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.

Source: http://www.minyanville.com/trading-and-investing/stocks/articles/Stock-Downgrades253A-MasterCard-Not-Longer-Quite/5/2/2013/id/49593

La Salle University the voice Denny Hamlin My Chemical Romance Olympus Has Fallen Arnold Palmer Invitational 2013 arnold palmer invitational

Thursday, May 2, 2013

Potential novel treatment for influenza discovered: Scientists pursue new therapies as deadly H7N9 flu spreads in China

May 1, 2013 ? An experimental drug has shown promise in treating influenza, preventing lung injury and death from the virus in preclinical studies, according to University of Maryland School of Medicine researchers publishing in the journal Nature on May 1. The scientists found that a drug called Eritoran can protect mice from death after they have been infected with a lethal dose of influenza virus. The potential value of this drug as single therapy or in combination with antivirals is further supported by previous research that found that it is safe for use in humans.

The findings are of particular interest to scientists now that the latest deadly strain of flu, H7N9, is spreading in China -- 82 people in China had been infected with the new strain of flu virus as of April 26, and 17 had died.

Previous scientific studies have revealed that acute lung injury caused by the influenza virus is the result of an immune reaction mediated by a protein called Toll-like receptor 4 (TLR4). Senior author Stefanie Vogel, Ph.D., Professor of Microbiology and Immunology and Medicine at the University of Maryland, and colleagues previously demonstrated that mice that lack the ability to signal through TLR4 are highly refractory to influenza-induced lethality. In their new study, they extend these findings by showing that Eritoran -- a synthetic inhibitor of TLR4, originally developed by Eisai Inc. for treatment of sepsis -- improved clinical symptoms and prevented death when administered up to six days after infection with the influenza virus. Existing antiviral medications must be administered within two days of infection to be optimally effective.

Annual influenza epidemics are estimated to result in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths yearly worldwide. The virus is continually evolving and new variants give rise to seasonal outbreaks. Increasing resistance to existing antiviral therapies and the short time-frame in which these agents are effective highlight the critical need for new treatments, such as Eritoran. This study was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

"Currently, vaccines and antiviral medications are the two main approaches to preventing influenza," says Dr. Vogel. "Problems associated vaccine development may limit efficacy and/or vaccine availability. In addition, people suffering from influenza may not go to the doctor or to the emergency room in time for the antivirals to be effective. Also, as the flu adapts to resist existing treatments, we are in search of new therapies to save lives and prevent severe illness. Our research seems to show that Eritoran could provide doctors with a new tool in their flu-fighting toolbox, as well as several more days to treat the sickest of patients successfully. More basic research is needed, but we are hopeful that this medication could one day change the way that we treat severe influenza and possibly other pathogens that cause disease by a similar mechanism."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by University of Maryland Medical Center.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Kari Ann Shirey, Wendy Lai, Alison J. Scott, Michael Lipsky, Pragnesh Mistry, Lioubov M. Pletneva, Christopher L. Karp, Jaclyn McAlees, Theresa L. Gioannini, Jerrold Weiss, Wilbur H. Chen, Robert K. Ernst, Daniel P. Rossignol, Fabian Gusovsky, Jorge C. G. Blanco, Stefanie N. Vogel. The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature, 2013; DOI: 10.1038/nature12118

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/~3/Gg2NTwnMfBU/130501154440.htm

the sound of music celebration church new york auto show 2012 tulsa easter eggs pineapple upside down cake free ecards

Wednesday, May 1, 2013

Belkin's Mythical Thunderbolt Express Dock Is Finally Here

Nearly 600 days have passed since we first swooned over Belkin's Thunderbolt Express Dock all the way back in September 2011. (Really, it's been 595 days, but who's counting?) Well today, the long-promised, and long-delayed multi-port I/O hub for Macs is a thing you can actually buy. It's available this morning at Belkin.com for $300.

Read more...

    


Source: http://feeds.gawker.com/~r/gizmodo/full/~3/yP40LQLlhRU/belkins-mythical-thunderbolt-express-dock-is-finally-h-485687797

jeremy lin Sage Stallone Mermaid Body Found Celeste Holm Stephen Covey klimt bastille day

BlackBerry CEO Thorsten Heins Says Tablets ?Not A Good Business ...

BlackBerry CEO Thorsten Heins seems to be among the most transparent executives in tech in terms of showing his hand regarding future product plans, which may be partly because he doesn?t have much to lose at this point. In an interview yesterday, he downplayed tablet computing in what looks to be an indicator that BlackBerry will drop the PlayBook, its own lame duck tablet and the first of its devices to sport a QNX-based operating system.

Heins should?ve stuck to specifics, however, as he went way overboard and came off as though he was losing touch with reality in the interview as quoted by Bloomberg, with broad sweeping statements like ?In five years I don?t think there?ll be a reason to have a tablet anymore,? and ?[t]ablets themselves are not a good business model.?

Tablets may not be a good business model for BlackBerry, which took huge writedowns on BlackBerry PlayBook inventory, were forced to run massive fire sales with price cuts of up to $400 to clear out inventory, and even finally?discontinued?the entry-level 16GB version entirely. By any real measure, the PlayBook was and is a failed product. But to say tablets won?t last five years, or that they aren?t a good business model requires that you completely ignore Apple?s tremendous success with the iPad, including the 19.5 million iPads it sold last quarter, an all-time record that came in well above analyst estimates.

Heins has recently made remarks that indicate BlackBerry may be experimenting with alternate device form factors, possibly taking a cue from hybrid gadgets like the Asus PadFone which combine a smartphone and tablet or mini-notebook style device in one. Once again, Heins said that he would need a BlackBerry tablet to be a unique device in an increasingly crowded market.

BlackBerry may have blown it on the PlayBook, but trash-talking tablets in general is worse than sticking your head in the sand: it makes the company look hopelessly out of touch. There?s definitely a lesson to be learned in the fact that Apple is the only company that?s really been able to succeed with a tablet device, but that lesson isn?t that the tablet market is a write-off entirely.


BlackBerry (formerly Research in Motion) is a Canadian designer, manufacturer and marketer of wireless devices and solutions for the worldwide mobile communications market. The company is best known as the developer of the BlackBerry smart phone. Blackberry technology also enables a broad array of third party developers and manufacturers to enhance their products and services with wireless connectivity to data. Blackberry was founded in 1984. Based in Waterloo, Ontario, the company has offices in North America, Europe and Asia Pacific....

? Learn more

Source: http://techcrunch.com/2013/04/30/blackberry-ceo-thorsten-heins-says-tablets-not-a-good-business-model-evidently-forgetting-about-ipad/

Tsunami Lil Reese Hurricane Sandy Nyc Saanvi Venna vikings Colin Powell noaa

Game Changers: Brilliant Innovators Who Change The World

1Elon Musk

2James Cameron

3J. Craig Venter

4Dean Kamen

Source: http://www.popularmechanics.com/technology/engineering/news/game-changers?src=rss

the shins atomic clock john mccain game changer corned beef recipe rpi dst

German inflation down, door open for ECB rate cut

FRANKFURT, Germany (AP) ? The European Central Bank has a freer hand to cut its key interest rate now that official figures show German inflation dropped to an annual 1.1 percent in April.

The ECB tries to achieve an inflation rate of just under 2 percent for the 17 European Union countries that use the euro. Low inflation in the eurozone's biggest economy gives the ECB a stronger case if it chooses to cut its key rate Thursday from a record low of 0.75 percent to stimulate the economy.

Rate cuts can worsen inflation if done at the wrong time ? but Monday's figures suggest inflation is little threat right now.

Many economists think the bank is increasingly ready to cut its key rate because of signs the economy is not recovering from recession.

Source: http://news.yahoo.com/german-inflation-down-door-open-ecb-rate-cut-133512084.html

branson mo monkees songs rail gun harrisburg top chef texas great pacific garbage patch ben affleck and jennifer garner

Not just Austin, dammit (Offthekuff)

Share With Friends: Share on FacebookTweet ThisPost to Google-BuzzSend on GmailPost to Linked-InSubscribe to This Feed | Rss To Twitter | Politics - Top Stories News, RSS and RSS Feed via Feedzilla.

Source: http://news.feedzilla.com/en_us/stories/politics/top-stories/302298415?client_source=feed&format=rss

mario manningham williams syndrome hoya casa de mi padre corned beef and cabbage diners drive ins and dives jeff who lives at home